uniQure N.V.

QURE

NL0010696654

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
15.53 ^USD	-8.32%		+8.83%	-35.10%

Mar. 11	Mizuho Upgrades uniQure to Outperform From Neutral, Adjusts Price Target to $35 From $12	MT
Mar. 10	Chardan Raises Price Target on uniQure to $31 From $16, Keeps Buy Rating	MT

FDA tells UniQure study data insufficient for brain disorder therapy application

Published on 03/02/2026 at 07:16 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about uniQure N.V.

Mar. 11	Mizuho Upgrades uniQure to Outperform From Neutral, Adjusts Price Target to $35 From $12	MT
Mar. 10	Chardan Raises Price Target on uniQure to $31 From $16, Keeps Buy Rating	MT
Mar. 09	Top Premarket Gainers	MT
Mar. 09	RBC Capital Upgrades uniQure to Outperform From Sector Perform, Adjusts Price Target to $35 From $11, Keeps Speculative Risk	MT
Mar. 05	UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official	MT
Mar. 05	FDA official calls UniQure's Huntington's disease treatment a failure	RE
Mar. 05	U.S. FDA official says uniQure is performing a distorted or manipulated comparison in the mind of FDA	RE
Mar. 05	U.S. FDA official says uniQure is likely the latest company to make a failed therapy for Huntington's patients	RE
Mar. 05	US-listed shares of uniQure NV rise nearly 20%	RE
Mar. 04	FDA official says UniQure fell short on Huntington's trial, defends new study request	RE
Mar. 03	UniQure Shares Drop After Wells Fargo, Mizuho Downgrades	MT
Mar. 03	Chardan Cuts Price Target on uniQure to $16 From $53, Keeps Buy Rating	MT
Mar. 03	Wells Fargo Downgrades uniQure to Equalweight From Overweight, Adjusts Price Target to $15 From $60	MT
Mar. 03	Mizuho Downgrades uniQure to Neutral From Outperform, Adjusts Price Target to $12 From $33	MT
Mar. 02	Health Care Down on Retreat From Sector - Health Care Roundup	DJ

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâ€™s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâ€™s disease is in Phase I/II clinical study.

Employees

221

Sector

Biotechnology & Medical Research

More about the company